Please make sure that HealthWell currently has a fund for your diagnosis/indication and that your medication is covered under that fund by visiting our Disease Funds listing. If we do not have a fund that currently covers your diagnosis, please check back as we frequently open and reopen programs as funding becomes available. The Foundation is able to help patients receiving treatment for indications for which we currently have an open fund. We can only assist with medications that have been prescribed to treat the disease/covered diagnosis. You will be asked to provide the Foundation with the patient’s diagnosis, which must be verified by a physician, nurse practitioner, or physician assistant’s signature. The patient must receive treatment in the United States.
Acute Myeloid Leukemia
Status
ClosedThis fund is temporarily closed to new patients due to lack of sufficient funding. Please continue to visit our Disease Funds page often, as replenished funds reopen as quickly as possible. If you currently have a grant with HealthWell, your grant will remain active for the entire 12 month grant cycle or until you have exhausted your allocated grant amount, whichever comes first. You can continue to use your pharmacy card or submit requests for reimbursements during your designated grant cycle.
Fund Type
CopayPremium (Medicare Part B only)
Maximum Award Level
Pharmacy Card Fund
YesMinimum CopayReimbursement Amount
We encourage you to please use your HealthWell pharmacy card for any applicable charges as possible.
Minimum Premium
Reimbursement Amount
Household Income Limit
500% of the Federal Poverty Level(adjusted for household size and high
cost of living areas)
Treatments Covered
- Adriamycin
- Ayvakit
- Azacitidine
- Cladribine
- Clofarabine
- Clolar
- Cyclophosphamide
- Cycophosphamide Intra Sol
- Cytarabine
- Cytoxan
- Dacogen
- Daunorubicin
- Daurismo
- Decitabine
- Depocyt
- Dexamet/nacl
- Dexamethasone
- Dexamethasone Sodium Phosphate
- Dexpak
- Doubledex
- Doxorubicin
- Droxia
- Enasidenib
- Etopophos
- Etoposide
- Fludarabine
- Gemtuzumab Ozogamicin
- Glasdegib
- Hydrea
- Hydroxyurea
- Idamycin Pfs
- Idarubicin Hydrochloride
- Idhifa
- Ivosidenib
- Jakafi
- Locort
- Maxidex
- Methotrexate
- Mitoxantron
- Mylotarg
- Neosar
- Nexavar
- Nivestym
- Onureg
- Otrexup
- Ozurdex
- Rasuvo
- Ready Dexame
- Rezlidhia
- Rydapt
- Tabloid
- Thioguanine
- Tibsovo
- Toposar
- Tretinoin
- Trexall
- Vanflyta
- Venclexta
- Venetoclax
- Vesanoid
- Vidaza
- Vyxeos
- Xatmep
- Xospata
- Zarxio
- Zonacort
- Zyloprim
Fund Definition
Assistance with the prescription drugs and biologics used in the treatment of acute myeloid leukemia.
Grant Utilization
HealthWell estimates that patients use an average of $4,410 during their 12-month grant period for this disease area.
Do I Qualify?
HealthWell bases eligibility on an individual’s medical, financial and insurance situation. To qualify for HealthWell’s assistance, applicants must meet the following eligibility requirements:
-
-
To qualify for copayment assistance from HealthWell, you must have some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment. Please note that in order to qualify for premium assistance through this fund, you must have Medicare Part B. The Foundation will refer patients without prescription insurance to other programs, such as manufacturer patient assistance programs.
-
HealthWell assists individuals with incomes up to 300-500% of the Federal Poverty Level. The Foundation also considers the number in a household and cost of living in a particular city or state. If you believe you qualify for assistance, you may begin the application process here.
-
If you are receiving treatment in the U.S. and have met the eligibility criteria as listed, you are ready to apply! Please note that you will be asked to provide a Social Security Number in order to create a grant. This information is gathered to eliminate duplicate applications and is kept secure and confidential.
About Acute Myeloid Leukemia
Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but in most cases it quickly moves into the blood. Most cases of AML develop from cells that would turn into white blood cells (other than lymphocytes), but some cases of AML develop in other types of blood-forming cells. According to the American Cancer Society (ACS), AML can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles. “Acute” means that this leukemia can progress quickly if not treated, and would probably be fatal in a few months. “Myeloid” refers to the type of cell this leukemia starts from. Source: American Cancer Society
Additional Educational Resources
You may also visit our Resource List to view other copayment organizations that may provide assistance.
